Disc Medicine, Inc. $IRON Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 22.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,305,046 shares of the company's stock after acquiring an additional 236,800 shares during the period. Vanguard Group Inc. owned 3.78% of Disc Medicine worth $64,782,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in IRON. Price T Rowe Associates Inc. MD increased its holdings in shares of Disc Medicine by 23.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock valued at $88,421,000 after acquiring an additional 262,690 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company's stock worth $77,170,000 after purchasing an additional 467,988 shares during the last quarter. Woodline Partners LP boosted its holdings in Disc Medicine by 5.2% in the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company's stock worth $25,144,000 after purchasing an additional 19,538 shares during the last quarter. MPM Bioimpact LLC grew its position in Disc Medicine by 11.1% in the 4th quarter. MPM Bioimpact LLC now owns 346,401 shares of the company's stock worth $21,962,000 after purchasing an additional 34,640 shares during the period. Finally, Northern Trust Corp raised its stake in Disc Medicine by 9.5% during the 4th quarter. Northern Trust Corp now owns 187,017 shares of the company's stock valued at $11,857,000 after buying an additional 16,299 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IRON shares. Wedbush reaffirmed an "outperform" rating and issued a $90.00 price objective on shares of Disc Medicine in a report on Monday, July 21st. BMO Capital Markets increased their price target on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Truist Financial initiated coverage on Disc Medicine in a research report on Monday, July 21st. They set a "buy" rating and a $86.00 target price for the company. Raymond James Financial initiated coverage on shares of Disc Medicine in a report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 target price on the stock. Finally, Morgan Stanley boosted their price objective on Disc Medicine from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. One analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $98.30.

Disc Medicine Trading Up 0.6%

IRON traded up $0.37 on Tuesday, reaching $59.78. 227,981 shares of the company traded hands, compared to its average volume of 331,909. The firm has a fifty day simple moving average of $57.21 and a two-hundred day simple moving average of $51.71. The company has a quick ratio of 32.11, a current ratio of 32.11 and a debt-to-equity ratio of 0.05. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $68.73. The company has a market cap of $2.08 billion, a P/E ratio of -13.37 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.41). As a group, equities research analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 34,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the completion of the transaction, the chief executive officer directly owned 161,828 shares of the company's stock, valued at approximately $8,953,943.24. This trade represents a 17.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kevin Bitterman sold 2,287 shares of Disc Medicine stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $61.03, for a total transaction of $139,575.61. Following the sale, the director owned 590,621 shares of the company's stock, valued at approximately $36,045,599.63. The trade was a 0.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 135,909 shares of company stock worth $8,006,371 over the last quarter. Insiders own 3.64% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.